Építés alatt – nem éles oldal
Belépés
BefejeződöttKorai 1. fázis

Cocaine and Zolmitriptan

A legfontosabb adatok

Ki végzi
William Stoops
Hol
Lexington (Egyesült Államok)A helyszín megnézése
Azonosító
Állapot
Befejeződött
Fázis
Korai 1. fázis
Résztvevők
12 fő vett részt
Kezdés
2021. okt. 15.
Befejezés
2025. jan. 9.
A vizsgálat típusa
Beavatkozással járó, 4 csoportAz egyik csoport placebót (hatóanyag nélküli szert) kap, összehasonlításként.
A vizsgált kezelések
  • Cocaine
  • Placebo oral capsule
  • Zolmitriptan
A regiszteradat frissítve
2025. augusztus 5.

Ki vehet részt

Életkor
18 év – 55 év
Nem
Nők és férfiak
Egészséges önkéntesek
Részt vehetnek

A regiszter feltételei, szó szerint

Mind a 6 feltétel megnézéseKevesebb

Ki vehet részt

  • Recent cocaine use

Ki nem vehet részt

  • Females not currently using effective birth control
  • Current or past histories of substance use disorder that are deemed by the study physicians to interfere with study completion
  • History of serious physical disease, current physical disease, impaired cardiovascular functioning, chronic obstructive pulmonary disease, history of seizure or current or past histories of serious psychiatric disorder that in the opinion of the study physician would interfere with study participation will be excluded from participation
  • Abnormal screening outcome (e.g., ECG, blood chemistry result) that study physicians deem clinically significant
  • Contraindications to cocaine or zolmitriptan

Helyszínek itt: Egyesült Államok

  • University of KentuckyLexington, Egyesült Államok

A vizsgálatról

Mit akar kideríteni a vizsgálat

Cocaine potently inhibits the reuptake of serotonin (5-HT). Increased synaptic 5-HT resulting from this reuptake inhibition activates multiple 5-HT receptor subtypes. Some of these receptor subtypes have been implicated in the abuse-related effects of cocaine, including its primary reinforcing effects (i.e., cocaine taking behavior). 5-HT1b receptors, which are autoreceptors on 5-HT nerve endings that regulate 5-HT release and heteroreceptors that also mediate other neurotransmitter release, play a particularly important role in cocaine effects, likely because they are highly expressed in the mesocorticolimbic system. The 5-HT1b system displays profound dysregulation during both active cocaine use and abstinence. Initial preclinical research showed that selective 5-HT1b agonists enhanced the reinforcing and locomotor effects of cocaine during ongoing cocaine administration, but subsequent research showed that these agents robustly attenuated reinstatement of cocaine- and cue-primed cocaine seeking behavior. These findings have been replicated in rigorously conducted studies using multiple schedules of reinforcement and negative sucrose reinforcement controls across laboratories. Notably, though, these preclinical studies used compounds not approved for use in humans, hindering translation. Recently published data show that zolmitriptan, a commercially available selective 5-HT1b agonist migraine medication, also selectively attenuates the reinforcing and other abuse-related effects of cocaine, regardless of stage of use (i.e., ongoing or extinguished cocaine self-administration).

A teljes eredeti leírásKevesebb

Although a robust preclinical literature supports the premise that 5-HT1b activation reduces a number of cocaine-associated behaviors (e.g., self-administration, cocaine seeking), this area remains unstudied in humans. The overarching goal of this project is to advance these promising preclinical findings, specifically those with zolmitriptan, to a clinical population, thereby demonstrating that the 5-HT1b system plays a key role in the effects of cocaine in humans

A vizsgálat 4 csoportja

  • PlaceboPlacebo, összehasonlításként

    Subjects will be maintained on oral placebo. Cocaine will be administered acutely during placebo maintenance. Placebo will be administered acutely during placebo maintenance.

    Kezelés: Cocaine és Placebo oral capsule

  • Zolmitriptan Dose 1A vizsgált kezelés

    Subjects will be maintained on oral zolmitriptan dose 1. Cocaine will be administered acutely during zolmitriptan dose 1 maintenance. Placebo will be administered acutely during zolmitriptan dose 1 maintenance.

    Kezelés: Cocaine

  • Zolmitriptan Dose 2A vizsgált kezelés

    Subjects will be maintained on oral zolmitriptan dose 2. Cocaine will be administered acutely during zolmitriptan dose 2 maintenance. Placebo will be administered acutely during zolmitriptan dose 2 maintenance.

    Kezelés: Cocaine és Zolmitriptan

  • Zolmitriptan Dose 3A vizsgált kezelés

    Subjects will be maintained on oral zolmitriptan dose 3. Cocaine will be administered acutely during zolmitriptan dose 3 maintenance. Placebo will be administered acutely during zolmitriptan dose 3 maintenance.

    Kezelés: Cocaine és Zolmitriptan

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
Behavioral Effects of Drugs (Inpatient): 42 (Cocaine and Zolmitriptan)
A regiszteradat frissítve
2025. augusztus 5.